Short and Long Term Efficacy of Combined Cabergoline and Octreotide Treatment in Acromegalic Patients

Federal University of São Paulo

Status: Completed

Conditions: Acromegaly

Treatments: Drug: cabergoline

Study type: Observational

Funder types: Other

Identifiers

NCT01014793

Mattapr1

Details and patient eligibility

About

In acromegaly, nearly 40% of patients fail to control GH/IGF-I levels with somatostatin analogues (SA). Dopaminergic agonists (DA) are even less effective, but combination therapy with SA and DA normalizes IGF-I levels in 33-56% of patients in short-term studies. This study was designed to evaluate short and long term efficacy of cabergoline in controlling IGF-I levels in acromegalic patients receiving octreotide.

Enrollment: 19 patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Active disease, under octreotide treatment at least 9 months

Exclusion criteria

• Cabergoline allergy

Trial design

19 participants in 1 patient group

Responders to cabergoline

Description:

patients with active disease under octreotide treatment received addition of increasing doses of cabergoline (1.0, 2.0 and 3.5mg/week)

Treatment:

Drug: cabergoline